Pharmaceuticals Financial News

Shares of Gland Pharma Ltd.(up 1.23 per cent), Laurus Labs Ltd.(up 0.93 per cent), Sanofi India Ltd.(up 0.61 per cent), Lupin Ltd.(up 0.22 per cent) and Torrent Pharmaceuticals Ltd.(up 0.1 per cent) ended the day as top gainers in the pack.

NEW DELHI : New Delhi: With the Indian pharmaceutical industry increasingly coming under the scanner globally, the Central Drugs Standard Control Organisation (CDSCO) is conducting a major exercise for improving the quality, safety and efficacy of biological products. The apex drug regulator has come up with the latest guidelines on biological products such as vaccines, biological, and recombinant DNA products that are to be in tune with international guidelines including that of the World Health Organization (WHO) and regulators in other countries.

Suven Pharmaceuticals: Global private equity firm Advent International has merged two of its pharmaceutical portfolio firms, Cohance Lifesciences and Suven Pharmaceuticals, according to a joint announcement. The merged entity will have three distinct business units – Pharma CDMO, Spec Chem CDMO, and API+ (inclusive of formulations), the release said. For every 11 shares of Suven, 295 shares of Cohance will be allotted, as per the terms of the merger.

BSE. Advent entities shall own around 66.7% stake and the public shareholders will hold around 33% stake in the merged entity. This ratio is pre-ESOP dilution," the firms clarified in the release.

Stocks that traded heavily or had substantial price changes on Wednesday: Boston Beer, Urban Outfitters fall, Alcon, Axon Enterprise rise

Shares of Alkem Laboratories Ltd.(up 2.75 per cent), Torrent Pharmaceuticals Ltd.(up 2.03 per cent), Biocon Ltd.(up 2.02 per cent), Glenmark Pharmaceuticals Ltd.(up 1.53 per cent) and Natco Pharma Ltd.(up 1.18 per cent) ended the day as top gainers in the pack.

mining and mineral sector. Besides these, Annual Capacity Building Plan for Geological Survey of India (GSI) will be released during the event. First round of critical mineral bids was called in November 2023. This was made possible after an amendment to the Mines and Minerals (Development and Regulation) Act earlier this fiscal. The centre also notified 24 minerals as being Critical and Strategic for the country, demand for which are usually met by imports. Critical minerals cater to the needs of sectors like renewable energy, defence, agriculture, pharmaceutical, high-tech electronics, telecommunications, transport, and creation of gigafactories among others. The amendment allowed the centre to grant mineral concession and prioritise auction of these resources. The revenue generated from these auctions shall accrue to the State Governments. Subsequently, royalty rates of critical minerals were rationalized to encourage more participation in auctions.

KKR & Co. is exploring options including selling its controlling stake in India’s JB Chemicals & Pharmaceuticals Ltd. amid interest from potential buyers, according to people familiar with the matter. The US private equity firm is looking to hire financial advisers to help evaluate a sale of its 53.8% stake in the Mumbai-based company, the people said, asking not to be identified as the matter is private. Other buyout firms and industry players have shown preliminary interest in buying KKR’s stake, the people said. Shares of the company, which is known as JB Pharma, have climbed 68% in the past 12 months, valuing the firm at just over $3 billion.

Birla Corporation, Marksans Pharmaceuticals, Saregama India, Savita Oil Technologies and Jash Engineering. The brokerage firm advises buying these stocks at current market prices and add on dips, keeping a time horizon of 2-3 quarters.

Takeda Pharmaceutical is holding talks with Indian regulators to make its dengue vaccine available in the country, the drugmaker's global head of vaccines, Gary Dubin, told Reuters on Tuesday. «We are in talks with regulators and plan to start a clinical trial very soon,» said Dubin. The Japanese drugmaker plans to scale up the production of its dengue vaccine Qdenga through a partnership with Indian vaccine maker Biological E., the companies said earlier in the day.

NEW DELHI : Roche Pharma India, a subsidiary of the Swiss pharmaceutical giant Roche, has launched monoclonal antibody drug, Ocrevus (ocrelizumab) in India for the treatment of multiple sclerosis. The company said Ocrevus is the first disease-modifying therapy (DMT) for both relapsing multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) and targets 150,000-200,000 patients diagnosed with multiple sclerosis in India. The drug is being launched in India after almost seven years of it being approved by the US Food and Drug Administration (FDA) for global use.

Investors who were allotted Mankind Pharma Ltd shares during the initial public offering are a happy lot. After the stellar listing gain of about 32% on 9 May, the stock has continued its upward trajectory, soaring another 48% to date. Mankind derives more than 90% of its revenue from the domestic markets with popular brands such as Manforce (condoms), PregaNews (pregnancy test kit) and Gas-O-Fast (antacid powder) in its portfolio.

While the Nifty ended at 22,198, gaining 76.30 points or 0.34%, the 30-stock S&P BSE Sensex closed the session at 73,095, up by 305 points or 0.42%.

Balrampur Chini Mills Ltd.(up 2.08%), Bannari Amman Sugars Ltd.(up 0.28%) and EID Parry(India)Ltd.(up 0.17%) stood among the top gainers.

Also Read: FPI holdings of Indian stocks dip to a decadal low of 16.3% in January In the chemical sector, HDFC Securities has a ’Buy’ rating on Navin Fluorine, Galaxy Surfactants, Neogen Chemicals and Aether Industries. Here are stocks to buy in the chemical sector.

Ashneer Grover has taken a jibe at Anupam Mittal, the founder of Shaadi.com, over a comment on a recent episode of Shark Tank India Season 3. “Mittal saab ki, na, umr ho gayi hai! (Mr. Mittal, you see, has gotten old)," he said while responding to a live audience.

Sanofi India with a target price of Rs 9170. The current market price of Sanofi India Ltd. is Rs 9039.3. Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 20816.69 Crore) operating in Pharmaceuticals sector.

In this article

The deep freeze in biotech is beginning to thaw. About half a dozen biotechnology companies have gone public since the start of 2024, with some raising hundreds of millions of dollars. The jump-start to the new year is a welcome sign for the industry after a challenging two years fueled by layoffs, scientific hurdles and rising interest rates, investors say.

Also Read-Stock market today: Vodafone Idea shares dip ahead of board meeting to discuss fundraising. Buy or sell? Analysts at Motilal Oswal Financial Services said that aggregate net profit for pharma companies under their coverage universe were up 15.5% YoY in 3QFY24. Aggregate growth for domestic formulation was 12% y-o-y for companies under BNP Paribas coverage, which is highest in the last seven quarters.

long-term perspective, presents considerable challenges for many retail investors. The landscape of investment is ever-evolving, posing unique hurdles along the way. Despite these obstacles, Indian retail investors have navigated the terrain with confidence since the market downturn in 2020.